A Phase I Study of Intravaginally Administered Artesunate In Women With High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

Next Previous
Trial Profile

A Phase I Study of Intravaginally Administered Artesunate In Women With High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs Artesunate (Primary)
  • Indications Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 27 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Jul 2018.
    • 27 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 24 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top